{"id":"ssg-and-paromomycin-sulphate","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SSG and Paromomycin sulphate are a combination of an amino-guanidine and an aminoglycoside antibiotic, respectively. They inhibit protein synthesis in the parasite by binding to the ribosome, ultimately leading to the death of the parasite.","oneSentence":"SSG and Paromomycin sulphate work by inhibiting protein synthesis in the parasite.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:04.932Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of visceral leishmaniasis"}]},"trialDetails":[{"nctId":"NCT05957978","phase":"PHASE2","title":"LXE408 for Treatment of Visceral Leishmaniasis in Ethiopia, a Proof of Concept Study","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2024-03-29","conditions":"Primary Visceral Leishmaniasis","enrollment":52},{"nctId":"NCT04342715","phase":"","title":"A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of York","startDate":"2022-05-22","conditions":"Visceral Leishmaniasis","enrollment":216},{"nctId":"NCT03129646","phase":"PHASE3","title":"Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2018-01-24","conditions":"Visceral Leishmaniasis","enrollment":439},{"nctId":"NCT00255567","phase":"PHASE3","title":"Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2004-11","conditions":"Visceral Leishmaniasis","enrollment":1142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SSG and Paromomycin sulphate","genericName":"SSG and Paromomycin sulphate","companyName":"Drugs for Neglected Diseases","companyId":"drugs-for-neglected-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SSG and Paromomycin sulphate work by inhibiting protein synthesis in the parasite. Used for Treatment of visceral leishmaniasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}